Xconomy

JUNE 12, 2020

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. There, topics once as unanticipated as the remote nature of the meeting shared top billing: COVID-19 and racism.

San Diego 121

San Diego Conference Organization Incubator 121

Xconomy

APRIL 2, 2020

Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall. On Thursday the Cambridge, MA-based venture capital firm, best known for starting and spinning out biotechs, announced it had added $1.1

Venture Capital 143

Venture Capital Capital Develop Development 143

Xconomy

JANUARY 27, 2020

By month’s end, five more are anticipated to join the class of 2020 initial public offerings—and four of those are in life sciences, according to IPO research firm Renaissance Capital. So far this year four privately held companies have made the transition to trading on the public markets.

Westlake Village 109

Westlake Village Class Research Capital 109

Xconomy

NOVEMBER 22, 2019

Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.

Acquisition 69

Acquisition Sales San Diego Company 69

Xconomy

NOVEMBER 20, 2019

Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. Nearly half of respondents believe that political and policy uncertainty present the greatest risks in 2020, with the latest Brexit developments and approaching UK and US elections seeing concerns around political volatility growing.

Pricing 78

Pricing Invest Develop Development 78

Xconomy

JANUARY 31, 2020

If this week is any indication, the steady march of life science companies to Wall Street will continue in 2020. Black Diamond’s stock price rise shows that investors continue to be interested in companies developing kinase inhibitors for solid tumors, according to IPO research firm Renaissance Capital. Renaissance.

Research 51

Research Pricing Activity Capital 51

Xconomy

MAY 29, 2020

ASCO 2020 won’t be the Windy City gathering it usually is, but drug and diagnostics developers are still raring to share fresh data from their efforts in cancer immunotherapy, targeted treatments, and early-stage screening methods during the course of the three-day scientific program.

Screening 67

Screening Conference Research Course 67